Schering Corporation

Merck + Co., Inc.

Merck Sharp + Dohme Corp.

Michael P Graziano

Duane A Burnett

Harry R Davis

William J Greenlee

Samuel Chackalamannil

Yan Xia

Wenxue Wu

Tiruvettipuram K Thiruvengadam

Scott W Altmann

Xiaorui Yao

Maureen Laverty

Mariappan Chelliah

Nicholas J Murgolo

Tao Wang

Yuguang Wang

Martin C Clasby

John S Chiu

Margaret A Cascieri

Enrico P Veltri

Teddy Kosoglou

Luquan Wang

Madhu Chintala

Patricia J Hey

Gary A Chicchi

Anastasia Pavlovsky

Susan Bogdanowich-Knipp

The use of azetidinone compounds that are inhibitors of cholesterol absorption as tools for discovering and characterizing proteins involved in trafficking or absorption of cholesterol and/or cholesteryl esters in biological systems is presented. These compounds can serve as tools for competitive binding assays to discover and characterize other chemical agents useful as cholesterol absorption inhibitors. New compounds of the present invention are also highly efficacious inhibitors of cholesterol absorption.

Use of azetidinone compounds

A compound represented by the structural formula    Also disclosed are pharmaceutical compositions and combinations containing said compounds and their uses as thrombin receptor antagonists and binders to cannabinoid receptors.

Constrained himbacine analogs as thrombin receptor antagonists

We claim an isolated polypeptide having ability of binding with cholesterol. Said polypeptide is useful for investigating regulation of intestinal cholesterol absorption and cholesterol levels. Also, we claim a composition comprising said polypeptide bound to cholesterol or ezetimibe and a fusion protein comprising the polypeptide thereof.

NPC1L1 (NPC3) and methods of use thereof

A synthetic human glucagon (hGlu) binding protein designated hGlu.DELTA.252-259 binding protein is cloned, expressed and used in an in vitro assay to screen for compounds that bind to the synthetic binding protein, including compounds that specifically stimulate or inhibit the binding of glucagon to the synthetic receptor. The invention includes the assay, the synthetic binding protein used in the assay, DNA encoding the synthetic binding protein, cells expressing the synthetic binding protein, and compounds identified through the use of the synthetic binding protein.

Synthetic glucagon binding proteins

Growing community of inventors

Scotch Plains, NJ, United States of America

Michael P Graziano